Literature DB >> 21310372

New method of intracoronary adenosine injection to prevent microvascular reperfusion injury in patients with acute myocardial infarction undergoing percutaneous coronary intervention.

Marek Grygier1, Aleksander Araszkiewicz, Maciej Lesiak, Magdalena Janus, Jadwiga Kowal, Wlodzimierz Skorupski, Malgorzata Pyda, Przemyslaw Mitkowski, Stefan Grajek.   

Abstract

The aim of our study was to examine the role of a new, simple protocol of intracoronary adenosine administration performed during primary angioplasty on the immediate angiographic results and clinical course. A prospective, single-center, randomized, placebo-controlled trial of 70 consecutive patients (64 ± 14 years, 54 men) with acute myocardial infarction with ST-segment elevation undergoing primary percutaneous coronary intervention (PCI) was conducted. Patients were randomized to 2 groups. Group 1 (n = 35) received intracoronary adenosine (1 to 2 mg) with a hand injection through the guiding catheter 2 times: immediately after crossing the lesion of the infarct-related artery with guidewire and then after the first balloon inflation. Group 2 (n = 35) received placebo. The baseline clinical and angiographic characteristics of the 2 groups were similar. Percutaneous coronary intervention resulted in Thrombolysis In Myocardial Infarction grade 3 flow after PCI in 32 patients (91.4%) in the adenosine group and 27 patients (77.1%) in the placebo group (p = 0.059). Myocardial blush grade 3 was observed at the end of PCI in 23 patients (65.7%) in the adenosine group and 13 (37.1%) in the placebo group (p < 0.05). Resolution of ST-segment elevation (> 50%) was more frequently observed in the adenosine than in the placebo group: 27 (77%) versus 15 (43%), respectively (p < 0.01). In conclusion, intracoronary adenosine administration improved the angiographic and electrocardiographic results in patients with acute myocardial infarction with ST-segment elevation undergoing PCI. Adenosine administration seemed to be associated with a more favorable clinical course.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21310372     DOI: 10.1016/j.amjcard.2010.12.010

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  13 in total

1.  Evaluation of Short- and Long-Term Efficacy of Combined Intracoronary Administration of High-Dose Adenosine and Tirofiban during Primary Percutaneous Coronary Intervention.

Authors:  Yanbing Li; Qiang Li; Feiou Li; Min Zong; Guobin Miao; Xinchun Yang; Zichuan Tong; Jianjun Zhang
Journal:  Acta Cardiol Sin       Date:  2016-11       Impact factor: 2.672

Review 2.  A Narrative Review of the Classical and Modern Diagnostic Methods of the No-Reflow Phenomenon.

Authors:  Larisa Renata Pantea-Roșan; Simona Gabriela Bungau; Andrei-Flavius Radu; Vlad Alin Pantea; Mădălina Ioana Moisi; Cosmin Mihai Vesa; Tapan Behl; Aurelia Cristina Nechifor; Elena Emilia Babes; Manuela Stoicescu; Daniela Gitea; Diana Carina Iovanovici; Cristiana Bustea
Journal:  Diagnostics (Basel)       Date:  2022-04-08

3.  Early Administration of Intracoronary Nitroprusside Compared with Thrombus Aspiration in Myocardial Perfusion for Acute Myocardial Infarction: A 3-Year Clinical Follow-Up Study.

Authors:  Wei-Chieh Lee; Shyh-Ming Chen; Chu-Feng Liu; Chien-Jen Chen; Wen-Jung Chung; Shu-Kai Hsueh; Tzu-Hsien Tsai; Hsiu-Yu Fang; Hon-Kan Yip; Chi-Ling Hang
Journal:  Acta Cardiol Sin       Date:  2015-09       Impact factor: 2.672

Review 4.  Extracellular signalling molecules in the ischaemic/reperfused heart - druggable and translatable for cardioprotection?

Authors:  P Kleinbongard; G Heusch
Journal:  Br J Pharmacol       Date:  2014-11-24       Impact factor: 8.739

5.  The REFLO-STEMI trial comparing intracoronary adenosine, sodium nitroprusside and standard therapy for the attenuation of infarct size and microvascular obstruction during primary percutaneous coronary intervention: study protocol for a randomised controlled trial.

Authors:  Sheraz A Nazir; Jamal N Khan; Islam Z Mahmoud; John P Greenwood; Daniel J Blackman; Vijay Kunadian; Martin Been; Keith R Abrams; Robert Wilcox; A A Jennifer Adgey; Gerry P McCann; Anthony H Gershlick
Journal:  Trials       Date:  2014-09-25       Impact factor: 2.279

Review 6.  The impact of ischemia-reperfusion injury on the effectiveness of primary angioplasty in ST-segment elevation myocardial infarction.

Authors:  Aleksander Araszkiewicz; Marek Grygier; Maciej Lesiak; Stefan Grajek
Journal:  Postepy Kardiol Interwencyjnej       Date:  2013-09-16       Impact factor: 1.426

Review 7.  Clinical benefit of adenosine as an adjunct to reperfusion in ST-elevation myocardial infarction patients: An updated meta-analysis of randomized controlled trials.

Authors:  Heerajnarain Bulluck; Alex Sirker; Yoon K Loke; David Garcia-Dorado; Derek J Hausenloy
Journal:  Int J Cardiol       Date:  2015-09-09       Impact factor: 4.164

8.  Strategies to attenuate micro-vascular obstruction during P-PCI: the randomized reperfusion facilitated by local adjunctive therapy in ST-elevation myocardial infarction trial.

Authors:  Sheraz A Nazir; Gerry P McCann; John P Greenwood; Vijay Kunadian; Jamal N Khan; Islam Z Mahmoud; Daniel J Blackman; Martin Been; Keith R Abrams; Lorraine Shipley; Robert Wilcox; A A Jennifer Adgey; Anthony H Gershlick
Journal:  Eur Heart J       Date:  2016-05-04       Impact factor: 29.983

9.  Efficacy of Adenosine in Patients With Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A PRISMA-Compliant Meta-Analysis.

Authors:  Qijun Gao; Bo Yang; Yi Guo; Feng Zheng
Journal:  Medicine (Baltimore)       Date:  2015-08       Impact factor: 1.817

10.  Combined analysis of the safety of intra-coronary drug delivery during primary percutaneous coronary intervention for acute myocardial infarction: A study of three clinical trials.

Authors:  Krishnaraj S Rathod; Stephen Hamshere; Rayomand S Khambata; Mervyn Andiapen; Mark Westwood; Anthony Mathur; Amrita Ahluwalia; Daniel A Jones
Journal:  JRSM Cardiovasc Dis       Date:  2017-08-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.